S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

Reata Pharmaceuticals Stock Forecast, Price & News

+0.05 (+0.16%)
(As of 07/1/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
236,625 shs
Average Volume
612,520 shs
Market Capitalization
$1.11 billion
P/E Ratio
Dividend Yield
Price Target

Reata Pharmaceuticals Stock Forecast (MarketRank)

Analyst Rating
Moderate Buy
2.67 Rating Score
93.8% Upside
$59.00 Price Target
Short Interest
17.72% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.63mentions of Reata Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($8.34) to ($6.50) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.28 out of 5 stars

Medical Sector

236th out of 1,429 stocks

Pharmaceutical Preparations Industry

93rd out of 682 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive RETA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Reata Pharmaceuticals logo

About Reata Pharmaceuticals (NASDAQ:RETA)

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

RETA Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
6 Analysts


Net Income
$-297.39 million
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$11.49 million
Book Value
$5.11 per share


Free Float
Market Cap
$1.11 billion

Reata Pharmaceuticals Frequently Asked Questions

Should I buy or sell Reata Pharmaceuticals stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Reata Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" Reata Pharmaceuticals stock.
View analyst ratings for Reata Pharmaceuticals
or view top-rated stocks.

What is Reata Pharmaceuticals' stock price forecast for 2022?

6 brokers have issued 1 year target prices for Reata Pharmaceuticals' stock. Their RETA stock forecasts range from $35.00 to $112.00. On average, they predict Reata Pharmaceuticals' stock price to reach $59.00 in the next twelve months. This suggests a possible upside of 93.8% from the stock's current price.
View analysts' price targets for Reata Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How has Reata Pharmaceuticals' stock performed in 2022?

Reata Pharmaceuticals' stock was trading at $26.37 at the beginning of 2022. Since then, RETA stock has increased by 15.4% and is now trading at $30.44.
View the best growth stocks for 2022 here

When is Reata Pharmaceuticals' next earnings date?

Reata Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Reata Pharmaceuticals

How were Reata Pharmaceuticals' earnings last quarter?

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) posted its earnings results on Tuesday, May, 10th. The company reported ($2.03) EPS for the quarter, topping analysts' consensus estimates of ($2.26) by $0.23. The firm had revenue of $0.91 million for the quarter, compared to the consensus estimate of $1.55 million. Reata Pharmaceuticals had a negative trailing twelve-month return on equity of 137.52% and a negative net margin of 2,650.72%. The firm's revenue was down 3.2% on a year-over-year basis. During the same quarter last year, the firm posted ($1.86) earnings per share.
View Reata Pharmaceuticals' earnings history

Who are Reata Pharmaceuticals' key executives?

Reata Pharmaceuticals' management team includes the following people:
  • Mr. J. Warren Huff, Chairman & CEO (Age 68, Pay $642.4k)
  • Mr. Manmeet Singh Soni, COO, CFO & Pres (Age 44, Pay $1.15M)
  • Mr. Michael D. Wortley, Exec. VP & Chief Legal Officer (Age 74, Pay $563.22k)
  • Dr. Colin J. Meyer M.D., Exec. VP & Chief Innovation Officer (Age 43, Pay $742.5k)
  • Ms. Dawn Carter Bir, Exec. VP & Chief Commercial Officer (Age 51, Pay $569.42k)
  • Mr. Bhaskar Anand, VP & Chief Accounting Officer (Age 45)
  • Dr. W. Christian Wigley Ph.D., Sr. VP & Chief Scientific Officer
  • Mr. Dakota Gallivan, VP & Chief Healthcare Compliance Officer
  • Mr. Steve Harman, Sr. VP & Chief HR Officer
  • Ms. Elaine Castellanos, Consultant (LinkedIn Profile)

What is Warren Huff's approval rating as Reata Pharmaceuticals' CEO?

10 employees have rated Reata Pharmaceuticals CEO Warren Huff on Glassdoor.com. Warren Huff has an approval rating of 92% among Reata Pharmaceuticals' employees. This puts Warren Huff in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Reata Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Reata Pharmaceuticals investors own include Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Synlogic (SYBX), NVIDIA (NVDA), Basic Energy Services (BAS), Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO) and Archrock (AROC).

When did Reata Pharmaceuticals IPO?

(RETA) raised $60 million in an initial public offering (IPO) on Thursday, May 26th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO.

What is Reata Pharmaceuticals' stock symbol?

Reata Pharmaceuticals trades on the NASDAQ under the ticker symbol "RETA."

How do I buy shares of Reata Pharmaceuticals?

Shares of RETA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Reata Pharmaceuticals' stock price today?

One share of RETA stock can currently be purchased for approximately $30.44.

How much money does Reata Pharmaceuticals make?

Reata Pharmaceuticals (NASDAQ:RETA) has a market capitalization of $1.11 billion and generates $11.49 million in revenue each year. The company earns $-297.39 million in net income (profit) each year or ($8.350010) on an earnings per share basis.

How many employees does Reata Pharmaceuticals have?

Reata Pharmaceuticals employs 346 workers across the globe.

How can I contact Reata Pharmaceuticals?

Reata Pharmaceuticals' mailing address is 5320 LEGACY DRIVE, PLANO TX, 75024. The official website for Reata Pharmaceuticals is www.reatapharma.com. The company can be reached via phone at (972) 865-2219 or via email at [email protected].

This page (NASDAQ:RETA) was last updated on 7/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.